Physician profile
Marvin Greenbaum
NPI 1073620472
$1,056.07
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $440 · 2020: $177 · 2021: $321 · 2022: $118.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $425.96 | 2020-2022 | |
| Coopervision INC. | $117.82 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $114.68 | 2019-2021 | |
| Alcon Vision LLC | $108.52 | 2019-2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $77.01 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $43.19 | 2019-2020 | |
| Aerie Pharmaceuticals, INC. | $34.40 | 2019-2020 | |
| Akorn, INC. | $33.14 | 2019 | |
| Allergan, INC. | $30.30 | 2019 | |
| Ocular Therapeutix, INC. | $18.38 | 2019 | |
| Horizon Therapeutics Plc | $15.90 | 2021 | |
| Eyevance Pharmaceuticals LLC | $13.17 | 2019 | |
| Abb Con-Cise Optical Group LLC | $11.96 | 2019 | |
| Shire North American Group INC | $11.64 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marvin Greenbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.